No treatment available today cures any form of muscular dystrophy. The disease remains progressive and, in many forms, life-shortening. What science does show is that the treatment landscape has shifted dramatically in the last decade: the first gene therapy for Duchenne muscular dystrophy (DMD) received approval in 2023, several exon-skipping drugs are on the market, and CRISPR-based gene editing has restored dystrophin production in animal models and human cells. These advances represent real progress, but each comes with significant caveats about how much function it restores, how long its effects last, and who it helps.
Why Muscular Dystrophy Is Hard to Cure
Muscular dystrophy is not one disease. The term covers a group of genetic disorders that cause progressive muscle weakness and wasting. DMD, the most common and severe childhood form, results from mutations in the gene that produces dystrophin, a protein that acts like structural scaffolding inside muscle cells. Without dystrophin, the outer membrane of muscle fibers becomes fragile and tears during normal contraction and relaxation, eventually killing the cell.1PubMed Central. Reduced Sarcolemmal Membrane Repair Exacerbates Striated Muscle Pathology in a Mouse Model of Duchenne Muscular Dystrophy Over years, muscle tissue is replaced by scar tissue and fat, and the damage is essentially irreversible once it occurs.
Other forms of muscular dystrophy involve entirely different genes. The limb-girdle muscular dystrophies alone involve at least 31 identified genetic loci, each affecting different proteins involved in muscle structure or function.2PubMed Central. Genetic basis of limb-girdle muscular dystrophies: the 2014 update Facioscapulohumeral dystrophy (FSHD) stems from abnormal expression of a gene that is normally silenced. Myotonic dystrophy involves toxic RNA repeats that disrupt cellular machinery. A “cure for muscular dystrophy” would require dozens of different cures, each tailored to a specific genetic defect. Most research funding and drug development has concentrated on DMD, which means the therapies discussed here mostly apply to that one form.
Standard Care Still Matters
Before diving into experimental therapies, it is worth noting that conventional management has substantially changed the trajectory of DMD over the past few decades. Glucocorticoids (steroids like prednisone and deflazacort) remain the backbone of treatment. They do not fix the genetic defect, but they slow the loss of muscle function and delay milestones like loss of walking ability. A large prospective study found that patients treated with glucocorticoids for a year or longer had roughly half the odds of dying compared with untreated patients, along with reduced risk of losing key mobility milestones across the lifespan.3PubMed. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study That is not a cure, but it is a meaningful difference in quality of life and years lived.
Cardiac care, respiratory support, and physical therapy round out the standard-of-care picture. These interventions have extended the median lifespan for people with DMD from the late teens into the late twenties and sometimes beyond. Any future curative therapy will still need to work alongside this foundation, not replace it overnight.
Gene Therapy and the Elevidys Story
The dystrophin gene is enormous, far too large to fit inside the viral delivery vehicles (called AAV vectors) that gene therapy relies on. Researchers solved this by engineering a shortened version called micro-dystrophin, which retains enough of the protein’s key regions to partially protect muscle cells. In 2023, the FDA approved Elevidys (delandistrogene moxeparvovec), the first gene therapy for DMD, making it a landmark moment for the field.4PubMed Central. AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects
The results, though, are genuinely mixed. In its phase 3 trial (EMBARK), Elevidys did produce micro-dystrophin protein in patients’ muscles. Biopsies taken 12 weeks after treatment showed an average of about 34% of normal dystrophin levels in treated patients, compared with zero in the placebo group.5Nature Medicine. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial The problem was that the trial failed to hit its primary clinical endpoint, meaning the functional improvement seen in treated patients was not large enough to reach statistical significance compared with placebo on the main measure used.4PubMed Central. AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects The protein was getting into muscle, but whether it translated into meaningful clinical benefit remained debatable.
A separate, earlier trial using a different micro-dystrophin construct (rAAVrh74.MHCK7) in four children showed more encouraging results: over 80% of muscle fibers expressed the protein, and all four patients improved on functional assessments over the following year.6JAMA Neurology. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial That trial was tiny and uncontrolled, so it cannot carry the same weight as a phase 3 result, but it showed that higher levels of protein expression could correlate with functional gains.
The Durability Problem
Even when gene therapy successfully delivers a working gene, a major unanswered question is how long it lasts. The viral vectors used in gene therapy do not integrate their payload into the patient’s chromosomes in any reliable way. Instead, the therapeutic gene sits as a separate piece of DNA inside the cell. In tissues that do not divide much, this can work well for years. But dystrophic muscle is constantly cycling through damage and repair, with new muscle cells replacing old ones. Each time a new cell forms, the therapeutic gene from the original treatment can be lost. Preclinical work has shown that this cycle of degeneration and regeneration actively depletes the delivered gene over time, and that the decline in dystrophin expression may result not from an immune attack but simply from the ongoing pathological process in the muscle itself.7Frontiers in Neurology. Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence
Redosing would be the obvious fix, but current AAV-based gene therapies cannot simply be given again. The first dose triggers an immune response against the viral shell, and any subsequent dose would be rapidly neutralized by the body’s own antibodies, or worse, provoke a harmful immune reaction.8PubMed Central. Nonclinical strategies and considerations to enable the redosing of gene therapies Researchers are working on strategies to suppress this immune memory or use different viral shells for a second dose, but none are clinically available yet. This means gene therapy for DMD is currently a one-shot treatment whose benefits may fade.
Exon Skipping Drugs
A different strategy sidesteps the need for a new gene entirely. Many DMD mutations involve deletions that throw the genetic instructions out of reading frame, producing a premature stop signal that halts dystrophin production. Exon-skipping therapy uses short pieces of synthetic genetic material (antisense oligonucleotides) to trick the cell’s splicing machinery into skipping over the problematic section, restoring the reading frame so that a shorter but partially functional dystrophin protein can be made.9PubMed Central. Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy The result is something closer to Becker muscular dystrophy, a milder form of the disease, rather than a complete fix.
Several exon-skipping drugs have received FDA approval, including eteplirsen (targeting exon 51), golodirsen (exon 53), viltolarsen (exon 53), and casimersen (exon 45). Each one applies only to the subset of patients whose specific deletion is amenable to that particular skip. These approvals were largely based on the ability to produce small amounts of dystrophin on muscle biopsy, not on definitive proof of clinical benefit in large trials.10PubMed Central. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy The drugs require ongoing weekly infusions and produce modest levels of dystrophin. Whether that modest production changes the long-term disease course remains an open question, and next-generation versions designed to boost uptake into muscle cells are in development.
Readthrough Therapy for Nonsense Mutations
About 10-15% of DMD cases are caused not by deletions but by point mutations that create a premature stop signal in the genetic code. Readthrough drugs work by coaxing the cell’s protein-making machinery to ignore these stop signals and continue building the full-length dystrophin protein.11PubMed Central. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124) The concept is elegant because it could work regardless of where in the gene the stop mutation sits.12PubMed Central. Read-through approach for stop mutations in Duchenne muscular dystrophy. An update
Ataluren (marketed as Translarna) was the furthest along this path and received conditional approval in Europe. In a phase 2a study, patients showed an average increase of about 11% in dystrophin expression after 28 days of treatment, with roughly 61% of patients showing at least some positive change.13PLOS ONE. Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy However, ataluren’s European marketing authorization was later withdrawn following further regulatory review. The readthrough approach faces an uphill battle: the amount of functional protein produced has generally been small, and translating that into measurable clinical improvement has proven difficult.
CRISPR Gene Editing
Gene therapy delivers a working gene alongside the broken one. CRISPR, by contrast, aims to fix the broken gene itself. Using CRISPR-Cas9, researchers can cut the DNA at precise locations to remove, replace, or rearrange the mutated portions of the dystrophin gene. In human cells and in mouse models of DMD, this approach has successfully restored dystrophin expression.14PubMed Central. CRISPR Correction of Duchenne Muscular Dystrophy Ideally, a single CRISPR treatment could permanently correct the mutation in a patient’s own cells, which would be a genuine cure.15PubMed Central. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy
The reality is more complicated. Delivering the CRISPR components to every affected muscle cell in the body is a massive logistical challenge. The editing tools still need to reach enough cells to make a functional difference, and they face the same viral delivery and immune-response obstacles as gene therapy. Off-target edits, where CRISPR cuts in unintended locations, remain a safety concern. Preclinical results have been promising, but significant hurdles around delivery efficiency and long-term safety stand between animal models and routine clinical use.16Global Medical Genetics. The Role of CRISPR/Cas9 in Revolutionizing Duchenne’s Muscular Dystrophy Treatment: Opportunities and Obstacles No CRISPR therapy for DMD has yet entered a pivotal clinical trial in humans.
Strategies That Work Around Dystrophin
Not all research focuses on fixing or replacing the dystrophin gene directly. Several alternative strategies aim to protect or strengthen muscle through other pathways.
Utrophin is a protein closely related to dystrophin that is naturally present in muscle but normally found only at certain specialized junctions. If utrophin could be coaxed to spread across the entire muscle cell membrane, it might compensate for missing dystrophin. This approach has the advantage of being mutation-agnostic: it does not matter what specific dystrophin mutation a patient has. In mice, boosting utrophin expression has led to improvements in muscle function, and a recent study using a targeted activation system in primates showed a twofold increase in utrophin expression in skeletal muscle with no significant side effects.17Nature Communications. Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy This line of work is still preclinical, but its mutation-independent nature makes it attractive as either a standalone therapy or a complement to dystrophin restoration.18PubMed Central. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies
Myostatin is a natural protein that limits muscle growth. Blocking myostatin in dystrophic mice increased muscle mass, size, and strength while reducing signs of muscle degeneration.19Nature. Functional improvement of dystrophic muscle by myostatin blockade Genetically engineering mice to produce a myostatin inhibitor produced similar benefits: bigger muscles, less cellular damage, and recovered strength.20PubMed. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice These animal results were exciting, but clinical trials of myostatin inhibitors in DMD patients have so far produced mixed results. One phase 2 trial of domagrozumab, an anti-myostatin antibody, found that treated patients were somewhat less likely to lose the ability to perform specific functional tasks over 48 weeks compared with placebo, but the overall effects were modest.21PubMed Central. Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial
Stem Cell Therapy
The idea of transplanting healthy muscle-forming cells into dystrophic muscle has been pursued for decades. In theory, donor stem cells could fuse with existing muscle fibers and supply the missing dystrophin. Several cell types have been investigated, including muscle-derived stem cells, mesenchymal stem cells from umbilical cord and other tissues, and cells reprogrammed from a patient’s own skin or blood.22PubMed Central. Stem cell therapy for muscular dystrophies The results so far have been mixed at best. Getting transplanted cells to survive, migrate throughout the body’s muscles, and integrate in sufficient numbers remains a formidable challenge. Immune rejection is another barrier when using donor cells. Stem cell therapy for DMD is still largely in the optimization stage, with researchers testing different cell types and pre-treatment strategies to improve engraftment.23PubMed Central. Stem/progenitor cell-based therapy for Duchenne muscular dystrophy
The Heart Problem
Even if a treatment perfectly protected every skeletal muscle in the body, it would not be a cure unless it also addressed the heart. Cardiomyopathy is the leading cause of death in people with DMD.24PubMed Central. Combination S100A1 and ARC gene therapy as a treatment for Duchenne muscular dystrophy cardiomyopathy Dystrophin is needed in cardiac muscle just as much as in skeletal muscle, and as patients live longer thanks to improved respiratory and orthopedic care, heart failure has become an increasingly pressing concern. Many of the gene and cell therapies being tested primarily target skeletal muscle and do not reach the heart as effectively. Separate cardiac-focused gene therapy approaches are in early development. One recent preclinical study in mice used AAV vectors to deliver two protective proteins to the heart, resulting in improved cardiac function and longer survival.24PubMed Central. Combination S100A1 and ARC gene therapy as a treatment for Duchenne muscular dystrophy cardiomyopathy Addressing the heart and skeletal muscles simultaneously is likely necessary for anything approaching a true cure.
What About Other Types of Muscular Dystrophy?
Most of the therapies described above were developed specifically for DMD. People living with other forms of muscular dystrophy have far fewer options in the pipeline, though this is starting to change. Investigational RNA-based therapies are being developed for FSHD, targeting the aberrant DUX4 gene that drives that disease, and for myotonic dystrophy type 1, targeting the toxic RNA repeats underlying that condition.25NeurologyLive. 8 Emerging Therapies Shaping the Muscular Dystrophy Treatment Landscape These are early-stage programs, and none are close to approval. For the limb-girdle dystrophies, the sheer number of genetic subtypes makes drug development even more fragmented: each subtype may eventually need its own gene replacement or correction strategy.
Exercise and Physical Rehabilitation
For people living with muscular dystrophy today, physical rehabilitation is not a theoretical future treatment but a present-day intervention. There has long been debate about whether exercise is safe for dystrophic muscles, since the underlying defect makes fibers more susceptible to damage. The evidence, while limited, suggests that carefully structured exercise programs can improve muscular strength and endurance without causing harm. A meta-analysis across several types of muscular dystrophy found a significant benefit for walking endurance with exercise.26Frontiers in Neurology. Effect of Muscular Exercise on Patients With Muscular Dystrophy: A Systematic Review and Meta-Analysis of the Literature A pilot study specifically in boys with DMD found that a 12-week mild-to-moderate intensity home exercise program improved knee strength and function with no signs of muscle damage.27PubMed Central. Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy The overall certainty of this evidence remains low, and more research is needed, but the old advice to avoid exercise altogether has given way to a more nuanced understanding that the right kind of activity can help.28PubMed Central. Exercise Training in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis
Assistive Technology and Daily Independence
While researchers work toward treatments that slow or reverse the disease, technology is making a real difference in the lives of people who have already lost significant function. Wearable upper-limb assistive devices, such as mobile arm supports, have been shown to significantly improve performance in daily activities for people with neuromuscular diseases.29Frontiers in Bioengineering and Biotechnology. The Effectiveness of Wearable Upper Limb Assistive Devices in Degenerative Neuromuscular Diseases: A Systematic Review and Meta-Analysis In a pilot study of mobile arm supports specifically in DMD, eating and drinking were the activities most often improved, and three of four participants gained meaningful independence in daily tasks.30PubMed. Mobile arm supports in Duchenne muscular dystrophy: a pilot study of user experience and outcomes Simple robotic devices, paired with customized control methods, have also opened up leisure and social opportunities for adolescents with neuromuscular diseases in both indoor and outdoor settings.31PubMed Central. Exploring the psychosocial impact of simple robotic assistive technology on adolescents with neuromuscular disease
These technologies do not change the disease itself, but they change what daily life looks like for people who have it. For someone who cannot lift a fork, an arm support that restores that ability is transformative on a very personal level.
The Cost of Treatment
Even where targeted therapies exist, access is a real concern. Total annual spending on targeted DMD therapies in the United States rose from about $40 million in 2016 to over $629 million in 2022, driven by the introduction of exon-skipping drugs and gene therapy. The average total annual cost per treated patient climbed from roughly $312,000 to nearly $590,000 over that period.32PubMed Central. Spending on Targeted Therapies for Duchenne Muscular Dystrophy Gene therapy, as a one-time treatment, carries an even higher sticker price. Out-of-pocket costs for insured families averaged around $142 per year, meaning insurance was absorbing most of the burden, but the sustainability of these price trajectories for rare-disease drugs is an ongoing policy debate. For families outside the United States or without adequate insurance, many of these treatments are effectively unreachable.
Why Animal Models Do Not Always Predict Human Results
A recurring theme in DMD research is that therapies that work impressively in mice often produce smaller or less consistent effects in people. The most commonly used animal model, the mdx mouse, carries a dystrophin mutation but has surprisingly mild disease compared with human DMD. It compensates through natural mechanisms that humans largely lack. The golden retriever model of muscular dystrophy (GRMD) mimics the human disease more faithfully in terms of symptom progression, muscle wasting, and tissue pathology, but it is far more expensive and logistically difficult to use in studies.33PLOS ONE. A standardised framework to identify optimal animal models for efficacy assessment in drug development Understanding these differences matters for interpreting headlines about promising preclinical results. A dramatic improvement in a mouse study may not translate proportionally to a human trial, and researchers in the field understand this gap well.34PubMed Central. Tracking progress: an update on animal models for Duchenne muscular dystrophy
This gap between animal and human results helps explain a frustrating pattern: decades of exciting preclinical work followed by clinical trials that show modest or ambiguous benefits. The science is not failing. It is running into the deep complexity of human biology, immune responses, and disease progression that no animal model fully captures.